Advanced Search

 

Study ID Status Title Patient Level Data
KG2105264 Completed A Mass Balance Study to Investigate the Metabolic Disposition of a 400 mg Single, Oral Dose of GSK189075 in Healthy Male Subjects
KG2107489 Completed A Randomized, Double-blind, Placebo-Controlled, Cross-Over Trial to Investigate the Effect of GSK189075 on Cardiac Repolarization as Compared to Placebo and a Single Dose of Moxifloxacin in Healthy Adult Subjects
KG2107494 Completed An open label, single-sequence, repeat-dose study to investigate the effects of GSK189075 on the pharmacokinetics of an oral contraceptive pill when coadministered to healthy female volunteers
KG2108197 Completed An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK189075
KG2109799 Completed A Randomized, Placebo-Controlled, Double-Blind, Repeat Dose, Dose Escalation trial to Investigate the Safety, Tolerability and Pharmacokinetics of Supratherapeutic Doses of GSK189075 Administered for 3 Days in Healthy Volunteers
KG2110243 Completed A Two-Week, Randomized, Double-Blind, Repeat-Dose, Parallel-Group Study to Evaluate the Safety and Tolerability of Metformin > 2000mg Co-Administered with Either GSK189075 500mg BID or GSK 189075 750mg BID to Subjects with Type 2 Diabetes Mellitus
KG2110375 Completed A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
KG219017 Completed A double blind, randomized, placebo controlled, single-dose escalation, first-time-in-human crossover study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ascending doses of GSK189075A in healthy subjects and in subjects with type 2 diabetes mellitus
KGI107465 Completed A double-blind, randomized, single ascending dose escalation, placebo-controlled, crossover study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK189075 administered to subjects with type 1 diabetes mellitus
KGO105858 Completed A Double-Blind, Randomized, Placebo-controlled Study to Evaluate Weight Loss, Safety, Tolerability and Pharmacokinetics in Obese Subjects Following 12-Week Dosing of GW869682, an SGLT2 inhibitor
KGW108201 Completed An exploratory study to evaluate weight loss, body composition changes, food intake and urine glucose excretion in healthy obese subjects over 8 weeks of dosing with GSK189075, GW869682 versus placebo
KGW111057 Completed An open-label, randomized, single dose, crossover study to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of modified release formulations of GSK189075 in healthy volunteers
KGW111083 Completed A double-blind, randomized, 6-sequence, 3-period crossover drug-drug interaction study to evaluate the pharmacokinetics of WELLBUTRIN SR (bupropion) and GSK189075 when co-administered or administered alone in healthy male volunteers
KSP10003 Completed A Phase I, Open-Label Study of SB-715992 in Combination with Docetaxel in Patients with Advanced Solid Tumors.
KSP10004 Completed A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination with Capecitabine on an Every 21-Day Schedule in Subjects with Advanced Solid Tumors
KSP10014 Completed A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination with Carboplatin on an Every 21-Day Schedule in Subjects with Advanced Solid Tumors.
KSP20001 Completed Phase II, Open Label Study of Ispinesib in Subjects with Advanced or Metastatic Breast Cancer
KSP20007 Completed A Phase II, Open-Label Study of Ispinesib in Subjects with Locally Advanced or Metastatic Platinum-Refractory or Platinum-Relapsed Non-Small Cell Lung Cancer (NSCLC)
KSP20008 Completed A Phase II, Open-Label Study of Ispinesib in Subjects with Platinum/Taxane-Refractory or Resistant Relapsed Ovarian Cancer
L4665-03 Completed A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients with Immune Thrombocytopenic Purpura (ITP) with an Open Label Extension
LAC103842 Completed An open label, multi-centre, single arm phase IV study to evaluate the antihypertensive effect of Lacidipine in mild to moderate essential hypertension patients with Type 2 diabetes in Korea
LAM100034 Completed A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Partial Seizures Study Listed on ClinicalStudyDataRequest.com
LAM100036 Completed A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients with Primary Generalized Tonic-Clonic Seizures Study Listed on ClinicalStudyDataRequest.com
LAM100118 Completed An Open-label Evaluation of LAMICTAL (lamotrigine) Monotherapy for the Treatment of Newly-diagnosed Typical Absence Seizures in Children and Adolescents Study Listed on ClinicalStudyDataRequest.com
LAM105379 Completed A pivotal single-dose randomised, parallel-group, open-label study to demonstrate bioequivalence of 300mg lamotrigine XR relative to 100mg + 200mg lamotrigine XR and to demonstrate lack of food effect on 300mg lamotrigine XR in healthy male and female volunteers Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.